It’s Hard to Treat What You Can’t See: The Molecular Diagnostics Perspective in Oncology

In everyday practice, it is common for pathology labs to evaluate >50% cytological specimens across solid tumors especially in lung and pancreatic cancers. Many of these cytological specimens require molecular profiling to help confirm diagnoses and guide treatment decisions.

Hear why a high Quantity Not Sufficient (QNS) from reference labs is unacceptable for your patients, especially after weeks of waiting, and how you can bring a robust amplicon-based comprehensive genomic profiling (CGP) in-house to ensure that you get answers when it counts.

Dr. Yi Ding, MD, PhD.
System and Core Lab Director, Molecular Diagnostics
Associate Director, Pathology Residency Program
Geisinger Medical Center